Table 2.
Group-level change in clinical measures pre- post 8 weeks of Lisdexamfetamine
| Measure (score range) | Wk 0 (n = 41) | Wk 0 (n = 33) | Wk 8 (n = 33) | Change, Cohen’s D ES, (95% CI) | |||
|---|---|---|---|---|---|---|---|
| M | SD | M | SD | M | SD | ||
| BE frequency (days/week) (0–7)** | 4.17 | 1.22 | 4.27 | 1.18 | 1.33 | 1.05 | 1.88 (1.3–2.4) |
| EDE-Q global (0–6)** | 4.64 | 1.03 | 4.60 | 1.03 | 2.92 | 1.09 | 1.60 (1.1–2.2) |
| HAM-D (0–54) | 5.41 | 4.29 | 4.70 | 3.83 | 3.52 | 4.64 | 0.28 (-0.1 – 0.6) |
| HAM-A (0–56) | 8.02 | 7.02 | 7.03 | 5.13 | 6.73 | 6.77 | 0.05 (−0.3 to 0.4) |
| ASRS total (0–18) | 7.83 | 5.45 | 7.09 | 5.16 | 7.03 | 5.52 | 0.02 (−0.3 to 0.4) |
| WHOQOL-BREF psychological (0–100)** | 46.14 | 14.89 | 47.00 | 14.05 | 59.38 | 12.88 | 0.93 (−1.34 to −0.51) |
Mean (M), standard deviation (SD), effect sizes (ES) and confidence intervals (CI) reported
NB. Effect sizes and confidence intervals are calculated based on completer sample only, n = 33
*p < .01, **p < .001